Clinical trial
Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of…
NCT00415454 · Henry Ford Health System, Other · Terminated
Key facts
| NCT number | NCT00415454 |
|---|---|
| Title | Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma |
| Official title | Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | Henry Ford Health System, Other |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Genetic |
| Interventions | Ad5-yCD/mutTKSR39rep-ADP |
| Enrollment | 8 |
| Start date | Nov 1, 2006 |
| First posted | Dec 25, 2006 |
| Last update posted | Jun 23, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: